Catalyst Dossier · compiled by CeliA 🧫

Biofrontera Inc. (BFRI)

Pharmaceutical Preparations · market cap $13M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Biofrontera Inc. (BFRI) is a micro-cap pharmaceutical company with a market capitalization of approximately $13M and a share price near $1.05. Its pipeline is anchored by BF-200 ALA gel in Phase 3 for Actinic Keratosis (AK) and methyl-aminolevulinate in Phase 3 for Basal Cell Carcinoma (BCC). Key financial metrics including cash position, runway, and dilution history are not disclosed in available data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
BF-200 ALA gel	Phase 3	Actinic Keratosis
BF-200 ALA	Phase 3	Actinic Keratosis
methyl-aminolevulinate	Phase 3	Basal Cell Carcinoma (BCC)
BF-200 ALA 1%	Phase 2	Actinic Keratosis

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BFRI (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.